0000899243-18-001188.txt : 20180117 0000899243-18-001188.hdr.sgml : 20180117 20180117164536 ACCESSION NUMBER: 0000899243-18-001188 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180116 FILED AS OF DATE: 20180117 DATE AS OF CHANGE: 20180117 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: IVERS-READ GILLIAN C CENTRAL INDEX KEY: 0001268304 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35347 FILM NUMBER: 18531897 MAIL ADDRESS: STREET 1: C/O PHARMION CORPORATION STREET 2: 2525 28TH STREET CITY: BOULDER STATE: CO ZIP: 80301 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Clovis Oncology, Inc. CENTRAL INDEX KEY: 0001466301 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 900475355 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5500 FLATIRON PARKWAY STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: (303) 625-5000 MAIL ADDRESS: STREET 1: 5500 FLATIRON PARKWAY STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-01-16 0 0001466301 Clovis Oncology, Inc. CLVS 0001268304 IVERS-READ GILLIAN C C/O CLOVIS ONCOLOGY, INC. 5500 FLATIRON PARKWAY, SUITE 100 BOULDER CO 80301 0 1 0 0 See Remarks Common Stock 2018-01-16 4 S 0 3000 59.16 D 183571 D The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 6, 2017. Executive Vice President of Technical Operations and Chief Regulatory Officer /s/ Gillian Ivers-Read 2018-01-17